Drug Profile

DWP 306001

Alternative Names: DWJ-306; DWP-306001; Enavogliflozin + DWC202010

Latest Information Update: 21 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Daewoong Pharmaceutical
Class Benzofurans; Cyclopropanes; Obesity therapies; Small molecules
Mechanism of Action Sodium-glucose transporter 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Obesity

Most Recent Events

16 Jul 2025 Phase-I development in Obesity in South Korea is still ongoing (Daewoong Pharmaceuticals pipeline, July 2025)
28 Mar 2025 No recent reports of development identified for phase-I development in Obesity in South Korea
06 Feb 2024 Daewon Pharmaceutical plans a phase II trial for Obesity in 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com